Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2012

01-03-2012 | Research Articles

Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas

Authors: Xue-Cheng Bi, Jiu-Min Liu, Hui-Chan He, Yong-Kang Ye, Zhao-Dong Han, Qi-Shan Dai, Yu-Xiang Liang, Chao-Cai, Jia-Hong Chen, Xi-Bin Chen, Guo-Qiang Qin, Guo-Hua Zeng, Wei-De Zhong

Published in: Clinical and Translational Oncology | Issue 3/2012

Login to get access
Metadata
Title
Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas
Authors
Xue-Cheng Bi
Jiu-Min Liu
Hui-Chan He
Yong-Kang Ye
Zhao-Dong Han
Qi-Shan Dai
Yu-Xiang Liang
Chao-Cai
Jia-Hong Chen
Xi-Bin Chen
Guo-Qiang Qin
Guo-Hua Zeng
Wei-De Zhong
Publication date
01-03-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0783-5

Other articles of this Issue 3/2012

Clinical and Translational Oncology 3/2012 Go to the issue

Educational Series / Red Series

Castration-resistant metastatic prostate cancer: current status and treatment possibilities

Special Article

Consensus of the Spanish Society of Radiation Oncology (SEOR) Brachytherapy Group on brachytherapy in Breast Cancer

Research Articles

Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians

Brief Research Article

Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain

Research Articles

Laryngeal cancer survival in Zaragoza (Spain): a population-based study

Research Articles

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits